Intraepidermal Nerve Fibers Are Indicators of Small-Fiber Neuropathy in Both Diabetic and Nondiabetic Patients
- Gary L. Pittenger, PHD12,
- Madhumita Ray, MS1,
- Niculina I. Burcus, MS1,
- Patricia McNulty, MD1,
- Baher Basta, MD1 and
- Aaron I. Vinik, MD, PHD12
- 1Department of Internal Medicine, The Strelitz Diabetes Institutes, Norfolk, Virginia
- 2Department of Pathology, Anatomy, and Neurobiology, Eastern Virginia Medical School, Norfolk, Virginia
- Address correspondence and reprint requests to Gary L. Pittenger, PhD, The Strelitz Diabetes Institutes, 855 W. Brambleton Ave., Norfolk, VA 23510. E-mail: pittengl{at}evms.edu
Abstract
OBJECTIVE—Small-fiber neuropathies may be symptomatic yet escape detection by standard tests. We hypothesized that morphologic changes in intraepidermal nerves would correlate with clinical measures of small-fiber neuropathy.
RESEARCH DESIGN AND METHODS—We studied 25 diabetic and 23 nondiabetic patients with neuropathy defined by signs, symptoms, and quantitative testing and 20 control subjects. Skin biopsies were obtained from forearm, thigh, proximal leg, and distal leg, and nerves identified using immunofluorescence with antibody to protein gene product (PGP) 9.5.
RESULTS—Mean dendritic length (MDL) (P < 0.01) and intraepidermal nerve fiber density (IENF) (P < 0.001) progressively decreased from proximal to distal sites only in patients with neuropathy. There was a significant reduction in IENF when comparing control subjects and patient groups in the distal leg (P < 0.001). MDL was significantly decreased in the thigh (P < 0.005) and in the proximal (P < 0.01) and distal (P < 0.002) leg in patients compared with control subjects. IENF was not significantly altered in diabetic patients of <5 years’ duration, but significantly decreased in patients with >5 years’ duration. MDL showed a linear decrease with increasing duration of diabetes. Distal leg IENF showed significant negative correlations with warm (P < 0.02) and cold (P < 0.05) thermal threshold, heat pain (P < 0.05), pressure sense (P < 0.05), and neurological disability score total sensory (P < 0.03) and total neuropathy (P < 0.03) values.
CONCLUSIONS—IENF was not significantly altered in these patients at <5 years’ duration of diabetes, but fell significantly after 5 years of diabetes. MDL exhibited a linear loss with time, suggesting a different mechanism of change. MDL and IENF together may prove a useful end point in therapeutic trials for neuropathy.
Footnotes
-
A.V. has received consultant’s fees from or served on the speaker’s bureaus for Pfizer, Genentech, Merck, Eli Lilly, Athena, Bristol Meyers Squibb, Knoll Pharmaceuticals, GlaxoSmithKline Beecham, Boston Medical Technologies, Neurometrix, Guilford Pharmaceuticals, R.W. Johnson Pharmaceutical Research Institute, Takeda, TEVA Pharmaceutical Industries, and AstraZeneca; and has received grant support from GMP-Endotherapeutics, the American Diabetes Association, the U.S. Department of Housing and Urban Development, the National Aeronautics and Space Administration, Eli Lilly, Parke-Davis, AstaMedica, GlaxoSmithKline Beecham, the National Institute on Aging, and R.W. Johnson.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
-
- Accepted May 15, 2004.
- Received September 12, 2003.
- DIABETES CARE














